Form4insider filings, from the source

SEC Form 4 · accession 0001209191-16-145419

Adamas Pharmaceuticals Inc · ADMS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Gregory T Went
Officer — Chief Executive Officer · Director
Period of report
Oct 5, 2016
Accepted (ET)
Oct 7, 2016 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockOct 5, 2016J117,450$0.00D146,208D
Common StockOct 5, 2016J195,400$0.00D195,392IBy Trust
Common Stockholding———80,000IGregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Bridget Elise Went
Common Stockholding———80,000IGregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Cora Margaret Went

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F2$0.665Oct 5, 2016J121,784D—Nov 16, 2021Common Stock121,784128,216D
Stock Option (Right to Buy)F3$0.665Oct 5, 2016J27,995D—Feb 22, 2022Common Stock27,99532,005D
Stock Option (Right to Buy)F4$8.995Oct 5, 2016J262,963D—Feb 20, 2024Common Stock262,963605,037D
Stock Option (Right to Buy)F5$17.31Oct 5, 2016J9,439D—Feb 24, 2025Common Stock9,43965,561D

Explanation of responses